The phase 3 SPR1NT trial is an ongoing open-label, single-arm study evaluating onasemnogene in presymptomatic patients (≤6 weeks of age) with a genetic diagnosis of SMA and 2 or 3 copies of survival motor neuron 2 gene.
Your search for major depressive disorder returned 2 results
Click on a filter below to refine your search. Remove a filter to broaden your search.
The system is currently being assessed for its use in stroke rehabilition in the Phase 3 supplemental study ‘E-FIT’, involving 60 patients.
Latest News Your top articles for FridayFor More Personalized News
Haymarket Medical NetworkTop Picks
Continuing Medical Education (CME/CE) Courses